Kyle Doherty

The expansion of screening criteria is an important step in decreasing lung cancer screening disparities in high-risk populations. Efforts to expand community outreach, overcome logistical barriers, and facilitate screening adherence must still be made, experts say.

An updated safety and efficacy analysis of the ongoing CLL14 trial showed that venetoclax plus obinutuzumab continues to be an effective treatment for patients with chronic lymphocytic leukemia and coexisting conditions.

Regardless of other identified driver genomic alterations, patients with heavily pretreated, advanced, non–small cell lung cancer achieved encouraging responses with patritumab deruxtecan.

Patient-reported outcome collections continue to yield more effective and personalized treatments for patients with cancer.

Current ASCO guidelines recommend that providers discuss the possibility of infertility with their patients as soon as possible before treatment begins.

Pacritinib helps relieve physical function-related symptoms in adult patients with myelofibrosis and moderate or severe thrombocytopenia.

The PARP inhibitor, niraparib, in conjunction with the VEGF inhibitor, bevacizumab, resulted in encouraging responses from patients with advanced ovarian cancer.

Investigators hope that the novel obecabtagene autoleucel, a second-generation CAR T-cell therapy may fill an unmet need by representing a durable treatment option for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

A Yale Cancer Center expert offers a quick glance at the metastatic urothelial cancer treatment landscape.

Axicabtagene ciloleucel improved the quality of life in patients with relapsed/refractory large B-cell lymphoma receiving the agent as a second-line therapy.

A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.

Patients with cancer should receive the entire COVID-19 vaccination as soon as possible, according to an expert at the 39th Annual Chemotherapy Foundation Symposium.

A phase 2 trial presented at the 2021 ESMO Annual Congress showed that Balstilimab plus Zalifrelimab induced superior response rates, duration of responses, and overall survival in patients with recurrent/metastatic cervical cancer.

More data are needed regarding the duration of response associated with this combination to make it a “mainstream” treatment option for patients, according to an expert from the University of Michigan Rogel Cancer Center.